Tag Archives: ACZ885

Novartis: ACZ885 led to 15% reduction in the risk of major adverse cardiovascular events (MACE) compared to placebo

Posted on 28, August 2017 by

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , ,

Novartis: ACZ885 reduced the rate of lung cancer incidence and mortality among study participants

Posted on 28, August 2017 by

Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , ,